The State Food and Drug Administration announced the second batch of drug rule of law publicity and education bases [three-minute quick overview of one-week medical highlights]

1.
Akeso announces a partnership with British biopharmaceutical company Summit Therapeutics signed a collaboration and license agreement to develop and commercialize
its bispecific antibody Evosi (PD-1/VEGF, AK112) in the United States, Canada, Europe and Japan.
Akeso reserves the right to develop and commercialize Ivaci except in the above regions, including in China
.
At the same time, Akeso has the co-branded rights
of the product in the agreement license area of Summit.
Under the agreement, Akeso will receive a $500 million down payment
.
The total value of the transaction, including development, registration and commercialization milestone payments, is expected to reach $5 billion
.
Akeso will also receive a low double-digit percentage of net sales as a royalty
for Ewosi.

2.
Shapuai issued an announcement that the company intends to participate in the investment of Jiusong Tangyuan with its own funds as a limited partner, and the company subscribed and contributed 60 million yuan, accounting for 85.
71%
of the total subscription of Jiusong Tangyuan.

3.
Betta Pharmaceutical issued an announcement that the company intends to invest in Beicheng Investment
with its own funds.
The total subscribed capital contribution of Beicheng Investment is 2 billion yuan, and the company will subscribe and contribute 999 million yuan as a limited partner of the partnership, with a subscribed capital contribution ratio of 49.
95
%.

4.
Dongcheng Pharmaceutical issued an announcement that its subsidiaries Midu Biotech and Gilles Tamagnan, Gu Zhuqin and other sellers signed the Share Purchase Agreement to acquire XING IMAGING, held by the seller, for a transaction amount of US$30.
2 million (including performance gambling rewards, equivalent to RMB 211 million).
LLC 100% equity
.

5.
Chengdu Pilot announced that its shareholding subsidiary Xianxian's derivatives intends to raise 65 million yuan, which is led by Yunren Investment, and 11 other investors participate, of which 5 investors are related parties
of the company.
Chengdu Pilot waived the pre-emptive subscription right for the capital increase and share increase of the prior derivatives, and after the completion of the capital increase and share increase, the equity ratio held by Chengdu Pilot in the first derivatives decreased from 40% to 29.
17%.

6.
Lizhu Group issued an announcement that it and its controlling shareholder, Health Yuan, originally planned to jointly invest and establish a partnership, but after careful consideration and full discussion by both parties, they have now decided not to establish a partnership and change it to joint investment to establish a joint venture
.
Lizhu Group and Health Yuan contributed $600 million and $400 million
in cash respectively.

7.
Meikecom Biologics announced the completion of a B+ round
of financing of more than 200 million yuan.
This round of financing was led by GF Qianhe, with the original shareholders China Life Equity Company and New Shang Capital continuing to invest, and the new investors Jiangyuan Investment, Guohai Capital and Guangdong Investment Fund co-investing
.
This round of financing will be mainly used for the clinical trials of the company's multiple vaccine pipelines, the construction of Shanghai human vaccine production base, and the expansion and improvement
of the company's talent team.

8.
Xiatong Biotech announced the completion of tens of millions of yuan of angel round financing, which is exclusively invested
by Danlu Capital.
Xiatong Biotech mainly develops characteristic nervous system-related stem cell drugs, and is committed to the treatment of demyelinating diseases
using induced pluripotent stem cells (iPSCs) technology.

Centralized procurement of medicines